Inhibitor Therapeutics (INTI) Enterprise Value (2012 - 2026)
Inhibitor Therapeutics' (INTI) quarterly Enterprise Value came in at -$1.3 million in Q1 2026, up 70.13% YoY from -$758821.5 in Q1 2025, and up 45.65% on a QoQ basis from -$2.4 million in Q4 2025.
Inhibitor Therapeutics (INTI) Enterprise Value (2012 - 2026) Analysis & Trends
Inhibitor Therapeutics (INTI) has 15 years of Enterprise Value data on file, last reported at -$1.3 million in Q1 2026.
- Quarterly Enterprise Value rose 70.13% year-over-year to -$1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.3 million (up 70.13% YoY) and the FY2025 annual result came in at -$2.4 million, up 57.63% from the prior year.
- Enterprise Value grew to -$1.3 million in Q1 2026, from -$2.4 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$24945.0 in Q2 2022 to a low of -$12.0 million in Q4 2022.
- A 5-year average of -$5.5 million and a median of -$5.6 million in 2024 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2022 — Enterprise Value soared 75.06% — and 2023, when it tumbled 40390.39%.
- Tracing INTI's Enterprise Value over 5 years: stood at -$12.0 million in 2022, then climbed by 26.03% to -$8.8 million in 2023, then surged by 36.57% to -$5.6 million in 2024, then surged by 57.63% to -$2.4 million in 2025, then jumped by 45.65% to -$1.3 million in 2026.
- The last three Enterprise Value figures came in at -$1.3 million (Q1 2026), -$2.4 million (Q4 2025), and -$3.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 2.12 Bn |
| 10 | Inhibitor Therapeutics | 15.64 Mn | 15.64 Mn | - | -515,758.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.29 Mn |
| Dec 31, 2025 | -2.38 Mn |
| Sep 30, 2025 | -3.00 Mn |
| Jun 30, 2025 | -3.70 Mn |
| Mar 31, 2025 | -4.32 Mn |
| Dec 31, 2024 | -5.61 Mn |
| Sep 30, 2024 | -6.40 Mn |
| Jun 30, 2024 | -7.10 Mn |
| Mar 31, 2024 | -7.68 Mn |
| Dec 31, 2023 | -8.84 Mn |
| Sep 30, 2023 | -9.54 Mn |
| Jun 30, 2023 | -10.10 Mn |
| Mar 31, 2023 | -10.78 Mn |
| Dec 31, 2022 | -11.95 Mn |
| Sep 30, 2022 | -53,058.00 |
| Jun 30, 2022 | -24,945.00 |
| Mar 31, 2022 | -36,438.00 |
| Dec 31, 2021 | -30,626.00 |
| Sep 30, 2021 | -53,287.00 |
| Jun 30, 2021 | -100,000.00 |